SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Protagonist Therapeutics, Inc.

SG&A Efficiency: A Decade of Strategic Growth

__timestampDr. Reddy's Laboratories LimitedProtagonist Therapeutics, Inc.
Wednesday, January 1, 2014387830000001860000
Thursday, January 1, 2015425850000002963000
Friday, January 1, 2016457020000006961000
Sunday, January 1, 20174637200000011779000
Monday, January 1, 20184691000000013697000
Tuesday, January 1, 20194889000000015749000
Wednesday, January 1, 20205012900000018638000
Friday, January 1, 20215455900000027196000
Saturday, January 1, 20226208100000031739000
Sunday, January 1, 202310593100000033491000
Monday, January 1, 202477201000000
Loading chart...

Unleashing insights

SG&A Efficiency: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Dr. Reddy's Laboratories Limited, a global player, and Protagonist Therapeutics, Inc., a burgeoning biotech firm, offer a fascinating contrast. Over the past decade, Dr. Reddy's has seen its SG&A expenses grow by approximately 173%, peaking in 2023. This reflects its expansive global operations and strategic investments. In contrast, Protagonist Therapeutics, with a more modest scale, has increased its SG&A expenses by nearly 1,700% since 2014, highlighting its aggressive growth strategy. However, data for 2024 is missing, leaving room for speculation on future trends. This analysis underscores the diverse strategies in managing operational costs, providing valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025